Page last updated: 2024-08-24

triazoles and buprenorphine

triazoles has been researched along with buprenorphine in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Basta-Kaim, A; Jurga, A; Kwiatkowski, K; Makuch, W; Mika, J; Piotrowska, A; Rojewska, E; Slusarczyk, J; Trojan, E	1
Backman, JT; Fihlman, M; Hagelberg, NM; Hemmilä, T; Kuusniemi, K; Laine, K; Laitila, J; Neuvonen, PJ; Olkkola, KT; Saari, TI	1
Bergeria, CL; Dunn, KE; Finan, PH; Gamaldo, CE; Hammond, AS; Huhn, AS; Strain, EC; Umbricht, A	1

Trials

2 trial(s) available for triazoles and buprenorphine

Article	Year
Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. European journal of clinical pharmacology, 2016, Volume: 72, Issue:11 Topics: Administration, Sublingual; Adult; Analgesics, Opioid; Antifungal Agents; Buprenorphine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Humans; Male; Pain; Single-Blind Method; Triazoles; Voriconazole; Young Adult	2016
Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Science translational medicine, 2022, 06-22, Volume: 14, Issue:650 Topics: Analgesics, Opioid; Azepines; Buprenorphine; Craving; Double-Blind Method; Humans; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Sleep; Substance Withdrawal Syndrome; Treatment Outcome; Triazoles	2022

Article

Year

Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.

European journal of clinical pharmacology, 2016, Volume: 72, Issue:11

Topics: Administration, Sublingual; Adult; Analgesics, Opioid; Antifungal Agents; Buprenorphine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Humans; Male; Pain; Single-Blind Method; Triazoles; Voriconazole; Young Adult

2016

Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.

Science translational medicine, 2022, 06-22, Volume: 14, Issue:650

Topics: Analgesics, Opioid; Azepines; Buprenorphine; Craving; Double-Blind Method; Humans; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Sleep; Substance Withdrawal Syndrome; Treatment Outcome; Triazoles

2022

Other Studies

1 other study(ies) available for triazoles and buprenorphine

Article	Year
Beneficial properties of maraviroc on neuropathic pain development and opioid effectiveness in rats. Progress in neuro-psychopharmacology & biological psychiatry, 2016, Jan-04, Volume: 64 Topics: Analgesics, Opioid; Animals; Astrocytes; Buprenorphine; CCR5 Receptor Antagonists; Cells, Cultured; Chronic Disease; Cyclohexanes; Cytokines; Disease Models, Animal; Drug Synergism; Ganglia, Spinal; Hyperalgesia; Lipopolysaccharides; Male; Maraviroc; Microglia; Morphine; Neuralgia; Rats, Wistar; Sciatic Nerve; Spinal Cord; Triazoles	2016

Article

Year

Beneficial properties of maraviroc on neuropathic pain development and opioid effectiveness in rats.

Progress in neuro-psychopharmacology & biological psychiatry, 2016, Jan-04, Volume: 64

Topics: Analgesics, Opioid; Animals; Astrocytes; Buprenorphine; CCR5 Receptor Antagonists; Cells, Cultured; Chronic Disease; Cyclohexanes; Cytokines; Disease Models, Animal; Drug Synergism; Ganglia, Spinal; Hyperalgesia; Lipopolysaccharides; Male; Maraviroc; Microglia; Morphine; Neuralgia; Rats, Wistar; Sciatic Nerve; Spinal Cord; Triazoles

2016